A Phase 2 clinical trial led by Ludwig Harvard's Stephen Hodi and Ludwig Memorial Sloan Kettering (MSK)'s Jedd Wolchok has found that the combination of two immunotherapies for first -
line treatment of advanced melanoma induces better responses and far longer progression - free survival than giving one of those drugs alone.
Moffitt Cancer Center researchers have laid the groundwork for a revolutionary new combination therapy for
the treatment of advanced melanoma — melanoma that can not be removed surgically or has spread to other areas of the body.
The FDA approved it last year for
the treatment of advanced melanoma, and we think it can help overcome the resistance that we've seen to pembrolizumab.
T - VEC, recently approved for
the treatment of advanced melanoma, is an oncolytic herpes simplex virus type 1 engineered to replicate selectively in tumor cells and express human granulocyte - macrophage colony - stimulating factor.